SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Reents Scott T – ‘3’ for 6/28/22 re: AbbVie Inc.

On:  Friday, 7/8/22, at 1:11pm ET   ·   For:  6/28/22   ·   As:  Officer   ·   Accession #:  1415889-22-7553   ·   File #:  1-35565

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 7/08/22  Reents Scott T                    3          Officer     2:14K  AbbVie Inc.                       SEC Connect

Initial Statement of Beneficial Ownership of Securities by an Insider   —   Form 3   —   SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 3           Initial Statement of Beneficial Ownership of        HTML     11K 
                Securities by an Insider --                                      
                form3-07082022_100701.xml/2.6                                    
 2: EX-24       Power of Attorney                                   HTML      7K

‘3’   —   Initial Statement of Beneficial Ownership of Securities by an Insider — form3-07082022_100701.xml/2.6



        

This ‘3’ Document is an XML Data File that may be rendered in various formats:

  Form 3    –   Plain Text   –  SEC Website  –  EDGAR System  –    XML Data    –  <?xml?> File
 
 
XML Data rendering:  Initial Statement of Beneficial Ownership of Securities by an Insider — form3-07082022_100701.xml/2.6
 
                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<ownershipDocument>
<schemaVersion> X0206 </schemaVersion>
<documentType> 3 </documentType>
<periodOfReport> 2022-06-28 </periodOfReport>
<noSecuritiesOwned> 0 </noSecuritiesOwned>
<issuer>
<issuerCik> 0001551152 </issuerCik>
<issuerName> AbbVie Inc. </issuerName>
<issuerTradingSymbol> ABBV </issuerTradingSymbol>
</issuer>
<reportingOwner>
<reportingOwnerId>
<rptOwnerCik> 0001937048 </rptOwnerCik>
<rptOwnerName> Reents Scott T </rptOwnerName>
</reportingOwnerId>
<reportingOwnerAddress>
<rptOwnerStreet1> 1 NORTH WAUKEGA </rptOwnerStreet1>
<rptOwnerStreet2></rptOwnerStreet2>
<rptOwnerCity> NORTH CHICAGO </rptOwnerCity>
<rptOwnerState> IL </rptOwnerState>
<rptOwnerZipCode> 60064 </rptOwnerZipCode>
<rptOwnerStateDescription></rptOwnerStateDescription>
</reportingOwnerAddress>
<reportingOwnerRelationship>
<isDirector> false </isDirector>
<isOfficer> true </isOfficer>
<isTenPercentOwner> false </isTenPercentOwner>
<isOther> false </isOther>
<officerTitle> SVP, Chief Financial Officer </officerTitle>
<otherText></otherText>
</reportingOwnerRelationship>
</reportingOwner>
<nonDerivativeTable>
<nonDerivativeHolding>
<securityTitle>
<value> Common Stock, $0.01 par value </value>
</securityTitle>
<postTransactionAmounts>
<sharesOwnedFollowingTransaction>
<value> 809 </value>
</sharesOwnedFollowingTransaction>
</postTransactionAmounts>
<ownershipNature>
<directOrIndirectOwnership>
<value> D </value>
</directOrIndirectOwnership>
<natureOfOwnership>
<value></value>
</natureOfOwnership>
</ownershipNature>
</nonDerivativeHolding>
</nonDerivativeTable>
<derivativeTable>
<derivativeHolding>
<securityTitle>
<value> Option (Right to buy) </value>
</securityTitle>
<conversionOrExercisePrice>
<value> 61.36 </value>
</conversionOrExercisePrice>
<exerciseDate>
<value> 2018-02-16 </value>
<footnoteId id="F1"/>
</exerciseDate>
<expirationDate>
<value> 2028-02-15 </value>
</expirationDate>
<underlyingSecurity>
<underlyingSecurityTitle>
<value> Common Stock </value>
</underlyingSecurityTitle>
<underlyingSecurityShares>
<value> 14140 </value>
</underlyingSecurityShares>
</underlyingSecurity>
<ownershipNature>
<directOrIndirectOwnership>
<value> D </value>
</directOrIndirectOwnership>
<natureOfOwnership>
<value></value>
</natureOfOwnership>
</ownershipNature>
</derivativeHolding>
<derivativeHolding>
<securityTitle>
<value> Option (Right to buy) </value>
</securityTitle>
<conversionOrExercisePrice>
<value> 114.36 </value>
</conversionOrExercisePrice>
<exerciseDate>
<value> 2019-02-15 </value>
<footnoteId id="F2"/>
</exerciseDate>
<expirationDate>
<value> 2028-02-14 </value>
</expirationDate>
<underlyingSecurity>
<underlyingSecurityTitle>
<value> Common Stock </value>
</underlyingSecurityTitle>
<underlyingSecurityShares>
<value> 11810 </value>
</underlyingSecurityShares>
</underlyingSecurity>
<ownershipNature>
<directOrIndirectOwnership>
<value> D </value>
</directOrIndirectOwnership>
<natureOfOwnership>
<value></value>
</natureOfOwnership>
</ownershipNature>
</derivativeHolding>
<derivativeHolding>
<securityTitle>
<value> Option (Right to buy) </value>
</securityTitle>
<conversionOrExercisePrice>
<value> 79.02 </value>
</conversionOrExercisePrice>
<exerciseDate>
<value> 2020-02-21 </value>
<footnoteId id="F3"/>
</exerciseDate>
<expirationDate>
<value> 2029-02-20 </value>
</expirationDate>
<underlyingSecurity>
<underlyingSecurityTitle>
<value> Common Stock </value>
</underlyingSecurityTitle>
<underlyingSecurityShares>
<value> 19470 </value>
</underlyingSecurityShares>
</underlyingSecurity>
<ownershipNature>
<directOrIndirectOwnership>
<value> D </value>
</directOrIndirectOwnership>
<natureOfOwnership>
<value></value>
</natureOfOwnership>
</ownershipNature>
</derivativeHolding>
<derivativeHolding>
<securityTitle>
<value> Option (Right to buy) </value>
</securityTitle>
<conversionOrExercisePrice>
<value> 93.50 </value>
</conversionOrExercisePrice>
<exerciseDate>
<value> 2021-02-20 </value>
<footnoteId id="F4"/>
</exerciseDate>
<expirationDate>
<value> 2030-02-19 </value>
</expirationDate>
<underlyingSecurity>
<underlyingSecurityTitle>
<value> Common Stock </value>
</underlyingSecurityTitle>
<underlyingSecurityShares>
<value> 28641 </value>
</underlyingSecurityShares>
</underlyingSecurity>
<ownershipNature>
<directOrIndirectOwnership>
<value> D </value>
</directOrIndirectOwnership>
<natureOfOwnership>
<value></value>
</natureOfOwnership>
</ownershipNature>
</derivativeHolding>
<derivativeHolding>
<securityTitle>
<value> Option (Right to buy) </value>
</securityTitle>
<conversionOrExercisePrice>
<value> 105.92 </value>
</conversionOrExercisePrice>
<exerciseDate>
<value> 2022-02-18 </value>
<footnoteId id="F5"/>
</exerciseDate>
<expirationDate>
<value> 2031-02-17 </value>
</expirationDate>
<underlyingSecurity>
<underlyingSecurityTitle>
<value> Common Stock </value>
</underlyingSecurityTitle>
<underlyingSecurityShares>
<value> 15527 </value>
</underlyingSecurityShares>
</underlyingSecurity>
<ownershipNature>
<directOrIndirectOwnership>
<value> D </value>
</directOrIndirectOwnership>
<natureOfOwnership>
<value></value>
</natureOfOwnership>
</ownershipNature>
</derivativeHolding>
<derivativeHolding>
<securityTitle>
<value> Option (Right to buy) </value>
</securityTitle>
<conversionOrExercisePrice>
<value> 144.54 </value>
</conversionOrExercisePrice>
<exerciseDate>
<value> 2023-02-17 </value>
<footnoteId id="F6"/>
</exerciseDate>
<expirationDate>
<value> 2032-02-16 </value>
</expirationDate>
<underlyingSecurity>
<underlyingSecurityTitle>
<value> Common Stock </value>
</underlyingSecurityTitle>
<underlyingSecurityShares>
<value> 11383 </value>
</underlyingSecurityShares>
</underlyingSecurity>
<ownershipNature>
<directOrIndirectOwnership>
<value> D </value>
</directOrIndirectOwnership>
<natureOfOwnership>
<value></value>
</natureOfOwnership>
</ownershipNature>
</derivativeHolding>
</derivativeTable>
<footnotes>
<footnote id="F1"> Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 4,714 shares on 2/16/2018, as to 4,713 shares on 2/16/2019 and as to 4,713 shares on 2/16/2020. </footnote>
<footnote id="F2"> Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 3,936 shares on 2/15/2019, as to 3,937 shares on 2/15/2020 and as to 3,937 shares on 2/15/2021. </footnote>
<footnote id="F3"> Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 6,490 shares on 2/21/2020, as to 6,490 shares on 2/21/2021 and as to 6,490 shares on 2/21/2022. </footnote>
<footnote id="F4"> Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 9,547 shares on 2/20/2021, as to 9,547 shares on 2/20/2022 and will become exercisable as to 9,547 shares on 2/20/2023. </footnote>
<footnote id="F5"> Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 5,176 shares on 2/18/2022, and will become exercisable as to 5,176 shares on 2/18/2023 and as to 5,175 shares on 2/18/2024. </footnote>
<footnote id="F6"> Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option will become exercisable as to 3,794 shares on 2/17/2023, as to 3,794 shares on 2/17/2024 and as to 3,795 shares on 2/17/2025. </footnote>
</footnotes>
<ownerSignature>
<signatureName> Steven L. Scrogham, attorney-in-fact for Scott T. Reents </signatureName>
<signatureDate> 2022-07-08 </signatureDate>
</ownerSignature>
</ownershipDocument>


↑Top
Filing Submission 0001415889-22-007553   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Sat., Apr. 27, 1:02:26.1pm ET